Here are 1-3 brief analogies for Predictive Oncology (POAI):

• Palantir for cancer drug discovery.
• Tesla for cancer drug development.
• Zillow for personalized cancer treatments.

• Helomics® AI Drug Discovery Platform: An AI-driven platform that leverages transcriptomic and proteomic data to predict drug response and identify novel oncology drug candidates.
• zPredicta Contract Research Services: Offers preclinical oncology research services, including cell-based assays and in vivo xenograft models, to accelerate drug development for other companies.

Predictive Oncology (POAI) primarily sells its services and technology to other companies in the biopharmaceutical and research sectors, rather than directly to individuals. Due to the nature of their business (drug discovery, AI platforms, contract research), specific customer names are often subject to confidentiality agreements and are not publicly disclosed by the company.

Based on Predictive Oncology's business model and offerings, their major customer categories are:

• Pharmaceutical Companies: Large and mid-sized pharmaceutical companies seeking to accelerate their oncology drug discovery and development pipelines. These companies utilize POAI's AI platforms (like Solomon AI™ and xFusion®) and contract research services (from Helomics®) to identify new drug candidates, optimize existing compounds, or gain deeper insights into drug resistance and efficacy.
• Biotechnology Companies: Other biotechnology firms, particularly those focused on oncology, precision medicine, or drug development, that leverage POAI's specialized platforms and expertise. These companies might partner with POAI for specific research projects, utilize their patient-derived tumor spheroid models, or license their AI capabilities to enhance their own R&D efforts.
• Academic and Research Institutions: Universities, cancer research centers, and other scientific institutions engaged in oncology research. While not always direct "customers" in the traditional sense, these institutions may collaborate with POAI or utilize their platforms and services for advanced research, seeking to bridge basic science discoveries with clinical applications.

null

Raymond F. Vennare, Chief Executive Officer and Chairman of the Board
Raymond F. Vennare became Predictive Oncology's CEO and Chairman of the Board on November 1, 2022, having served on the Board of Directors since September 2021. He has a long history of founding, advising, and leading companies in both the private and public sectors, ranging from bioinformatics, diagnostics, and therapeutic drug delivery to FDA-cleared medical devices. Mr. Vennare co-founded ThermalTherapeutic Systems, Inc. in 2006, serving as its President and CEO, and was previously CEO and Chairman of Cvergenx, Inc. His past roles also include President and CEO of ImmunoSite, Inc., Senior Vice President and Chief Information Officer of TissueInformatics, Inc., and President of VS/Interactive. He is also an Investment Partner in Inventeur, LLC.

Josh Blacher, Interim Chief Financial Officer
Josh Blacher is the Interim Chief Financial Officer for Predictive Oncology. He is a strategic and operational CFO with over 20 years of experience in leadership roles for both private and Nasdaq-listed companies, specializing in the life science and biotech sectors. He was also appointed CFO of BullFrog AI in December 2023.

Thomas McLaughlin, Chief Investment Officer
Thomas McLaughlin serves as Chief Investment Officer of Predictive Oncology and is also CIO of DNA Asset Management. He is recognized as one of the industry's foremost leaders in liquid crypto markets, with extensive experience trading and investing in digital assets since 2016. Prior to joining Predictive Oncology, he founded Coral Capital, a crypto asset management firm, and began his career as an investment banking analyst at Bank of America Merrill Lynch.

Sara Turken, JD, Senior Vice President & General Counsel
Sara Turken is the General Counsel for Predictive Oncology, bringing extensive experience as an accomplished legal executive in the life sciences and biotechnology sector. Her expertise spans corporate law, healthcare regulation, and strategic transactions. Ms. Turken has experience from other biotechnology companies such as Excision BioTherapeutics and Rocket Pharmaceuticals, and previously worked as a corporate associate at Covington & Burling and an investment banking associate at Credit Suisse.

Arlette H. Uihlein, MD, Senior Vice President, Translational Medicine and Drug Discovery, Medical Director
Dr. Arlette H. Uihlein is the Senior Vice President of Translational Medicine and Drug Discovery for Predictive Oncology and serves as the Site Leader of Helomics. She has also been the Medical Director of Helomics® Clinical and Research Labs since 2011.

The highly competitive and rapidly evolving landscape of AI-driven drug discovery, particularly within oncology, where numerous well-funded companies and established pharmaceutical players are developing sophisticated proprietary platforms. This intense competition poses an emerging threat as a competitor's platform could demonstrate superior efficacy, speed, or cost-effectiveness, thereby attracting partnerships, talent, and investor interest away from Predictive Oncology.

Predictive Oncology (POAI) focuses on AI-driven drug discovery and personalized oncology solutions. The addressable markets for its main products and services are significant and global.

• AI-Driven Drug Discovery and Development: The global AI in drug discovery market is projected to reach $1.1 billion in 2025, with oncology accounting for 20% of this revenue.
• Biomarker Discovery: The total biomarker discovery market is estimated at $51.5 billion globally in 2024, with a projected compound annual growth rate (CAGR) of 19.4% through 2030.
• Personalized Oncology Solutions and Services: While a specific global market size for Predictive Oncology's broad personalized oncology solutions (including AI-driven tools for patient stratification, treatment selection, and prediction of treatment response) is not explicitly stated as a single figure, the company's work with Helomics and its collaborations on specific cancers highlight segments within the broader oncology market. For example, the treatment market for thyroid cancer is expected to reach $2.1 billion by 2025.

Expected Drivers of Future Revenue Growth for Predictive Oncology (POAI)

Over the next 2-3 years, Predictive Oncology (POAI) anticipates several key drivers for future revenue growth, primarily centered on its artificial intelligence (AI) and machine learning capabilities in oncology drug discovery and development:

1. AI-Driven Drug Discovery and Repurposing Partnerships: Predictive Oncology is actively pursuing collaborations with biopharmaceutical companies to leverage its AI and machine learning platform for the repurposing of existing drugs in new cancer indications. The company has already demonstrated success in identifying promising repurposed drug candidates for breast and colon cancer.
2. Expansion and Commercialization of ChemoFx® Drug Response Assay: The company has recently launched its validated live cell ChemoFx® drug response assay in Europe and is expanding its availability in the United States. This assay is considered a crucial component for personalized cancer care and a significant part of Predictive Oncology's growth strategy.
3. Development and Commercialization of Novel 3D Cell Culture Technology: Revenue growth in Q1 2025 was notably driven by the completion of a tumor-specific 3D model. Predictive Oncology has also introduced an advanced 3D cell culture technology designed to mimic human tissue architecture more closely, which enhances the testing of drug candidates and is expected to contribute to future service revenue.
4. Discovery and Commercialization of Novel Oncology Biomarkers: POAI has broadened its AI and machine learning platform to include the discovery of novel oncology biomarkers. This expansion is supported by positive outcomes from a retrospective ovarian cancer study, suggesting potential new revenue streams through related licensing or partnerships.
5. Strategic Partnerships and Investments in AI Infrastructure: The company is focused on securing partnerships to further utilize its platform for drug development. Additionally, Predictive Oncology has engaged in private investment transactions to support its digital asset treasury strategy, which involves the ATH utility token of the Aethir ecosystem, aligning with its computational requirements for advanced AI-driven drug discovery.

Share Issuance

• In May 2020, Predictive Oncology executed a registered direct offering of 1,396,826 shares of common stock at $1.575 per share, raising approximately $2.2 million in gross proceeds.
• Effective September 30, 2025, the company completed a 1-for-15 reverse stock split, consolidating 11,436,201 outstanding shares into approximately 762,414 shares.
• As of October 29, 2025, Predictive Oncology filed a prospectus supplement to its at-the-market (ATM) program, allowing the sale of up to $18,330,000 in common stock, with approximately $2,417,337 of securities having been sold under this program in the prior 12 months.

Inbound Investments

• On October 7, 2025, Predictive Oncology closed two Private Investment in Public Equity (PIPE) transactions, raising approximately $343.5 million to initiate a digital asset treasury strategy.
• This funding included a cash PIPE of $50.8 million and a crypto PIPE with a nominal value of $292.7 million, composed of pre-funded warrants with approximately $173.3 million in discounted Aethir (ATH) token contributions.

Capital Expenditures

• Predictive Oncology's capital expenditures were relatively low historically, with -$0.3 million in 2020, -$0.91 million in 2021, -$0.42 million in 2022, -$0.02 million in 2023, and -$0.01 million in 2024.
• For the last 12 months (ending June 2025), capital expenditures amounted to -$6,478.
• The company projects capital expenditures of $3 million for fiscal year 2025.